US mRNA Therapeutics Market (By Type: Therapeutic Vaccines, Prophylactic Vaccines, Therapeutic Drugs; By Application: Respiratory Diseases, Oncology, Rare Genetic Diseases, Infectious Diseases, Others; By End-use: Research Organizations, Hospitals & Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2024-2033
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2024-2033
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Rare Genetic Diseases
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Infectious Diseases
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2024-2033
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
US mRNA Therapeutics Market
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market
5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. US mRNA Therapeutics Market, By Type
8.1. US mRNA Therapeutics Market, by Type, 2024-2033
8.1.1 Therapeutic Vaccines
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Prophylactic Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Therapeutic Drugs
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. US mRNA Therapeutics Market, By Application
9.1. US mRNA Therapeutics Market, by Application, 2024-2033
9.1.1. Respiratory Diseases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Rare Genetic Diseases
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. US mRNA Therapeutics Market, By End-use
10.1. US mRNA Therapeutics Market, by End-use, 2024-2033
10.1.1. Research Organizations
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. US mRNA Therapeutics Market, Trend Forecast
11.1. US
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. GSK plc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BioNTech SE
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CureVac N.V.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sangamo Therapeutics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Translate Bio, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Moderna, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Argos Therapeutics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arcturus Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca plc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample